Evommune Announces Late-Breaker Presentation of Phase 2 Data for EVO756 in Chronic Inducible Urticaria at Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress
(EVMM) --Company to host a webcast to review the full data set from Phase 2 trial -- PALO ALTO, Calif., Sept. 2, 2025 /PRNewswire/ -- Evommune, Inc., a clinical stage biotechnology company discovering and developing innovative therapies that target key drivers of chronic inflammatory diseases,...
Related Questions
How will the Phase 2 data for EVO756 influence Evommune's valuation and near‑term stock performance?
What are the primary efficacy and safety results presented, and how do they compare with current therapies for chronic inducible urticaria?
When is Evommune expected to update guidance on regulatory filing timelines and potential commercialization or partnership plans after the EADV 2025 presentation?